Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Inclusion Criteria: * Previously undergone Roux-en-Y gastric bypass (RYGB) surgery at least 6 months prior to screening * Previous diagnosis of post-bariatric hypoglycemia (PBH), requiring intake of oral carbohydrates. * Body mass index (BMI) ≤ 40 kg/m2 * Fasting plasma glucose between 72-106 mg/dL (4.0-6.0 mmol/l) Exclusion Criteria: * History of hypersensitivity reactions to glucagon or dasiglucagon or any of the excipients * History of insulinoma, pheochromocytoma, MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease. * Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m2 or end-stage renal disease at screening * Hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase ≥ 2.5 times the upper limit of normal (ULN) * Active malignancy, except for basal or squamous cell skin cancers * History of a cerebrovascular accident within 6 months prior to screening * History of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening. * Congestive heart failure, New York Heart Association Class III or IV * Concurrent administration of β-blocker therapy * Clinically significant ECG abnormalities at screening